Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SHAUN S BERGER

Allopathic & Osteopathic Physicians Pediatrics

NPI
1033228838
CMS profile
1189751
Location
SAN DIEGO, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$243.55

2 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $243.55 2

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
SANOFI PASTEUR INC. $132.92 1
Merck Sharp & Dohme LLC $110.63 1

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SHAUN S BERGER

NPI 1033228838 · CMS profile ID 1189751

Allopathic & Osteopathic Physicians / Pediatrics

SAN DIEGO, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1033228838?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SHAUN S BERGER, NPI 1033228838, CMS profile ID 1189751. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1033228838?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). SHAUN S BERGER, NPI 1033228838, CMS profile ID 1189751. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1033228838?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
SHAUN S BERGER, NPI 1033228838, CMS profile ID 1189751, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1033228838?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

2 matching records · $243.55 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 2 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–2 of 2.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Merck Sharp & Dohme LLC $110.6310/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944588651 CMS
SANOFI PASTEUR INC. $132.9206/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937358343 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2021 $121.98 1
PY2022 $243.55 2
PY2023 $188.64 4
PY2024 $159.46 8
PY2025 $223.45 6

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $219,980.52 64
PY2024 Principal investigator $163,066.66 24
PY2023 Principal investigator $26,808.70 6
PY2022 Principal investigator $13,574.72 4
PY2021 Principal investigator $65,759.08 6

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

64 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $1,440.00 12/31/2025 Non-covered Recipient Entity
PARADIGM CLINICAL RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Single-attack Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral Ubrogepant in the Acute Treatment of Migraine With or Without Aura in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202532761
Principal investigator 1 ABBVIE INC. $9.94 12/24/2025 Non-covered Recipient Entity
PARADIGM CLINICAL RESEARCH CENTERS
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202532032
Principal investigator 1 ABBVIE INC. $113.40 12/16/2025 Non-covered Recipient Entity
PARADIGM CLINICAL RESEARCH CENTERS
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202530552
Principal investigator 1 ABBVIE INC. $105.56 12/15/2025 Non-covered Recipient Entity
PARADIGM CLINICAL RESEARCH CENTERS
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202530494
Principal investigator 1 ABBVIE INC. $90.00 12/15/2025 Non-covered Recipient Entity
PARADIGM CLINICAL RESEARCH CENTERS
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202530502
Principal investigator 1 ABBVIE INC. $3,105.00 12/04/2025 Non-covered Recipient Entity
PARADIGM CLINICAL RESEARCH CENTERS
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202526540
Principal investigator 1 ABBVIE INC. $3,272.78 12/04/2025 Non-covered Recipient Entity
PARADIGM CLINICAL RESEARCH CENTERS
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202527572
Principal investigator 1 ABBVIE INC. $50.00 11/26/2025 Non-covered Recipient Entity
PARADIGM CLINICAL RESEARCH CENTERS
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202525466
Principal investigator 1 ABBVIE INC. $50.00 11/26/2025 Non-covered Recipient Entity
PARADIGM CLINICAL RESEARCH CENTERS
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202525480
Principal investigator 1 ABBVIE INC. $136.00 11/06/2025 Non-covered Recipient Entity
PARADIGM CLINICAL RESEARCH CENTERS
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202523255
Principal investigator 1 ABBVIE INC. $2,362.50 11/05/2025 Non-covered Recipient Entity
PARADIGM CLINICAL RESEARCH CENTERS
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202521717
Principal investigator 1 ABBVIE INC. $1,042.89 11/05/2025 Non-covered Recipient Entity
PARADIGM CLINICAL RESEARCH CENTERS
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202521719
Principal investigator 1 ABBVIE INC. $160.65 11/03/2025 Non-covered Recipient Entity
PARADIGM CLINICAL RESEARCH CENTERS
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202520017
Principal investigator 1 ABBVIE INC. $1,120.00 10/21/2025 Non-covered Recipient Entity
PARADIGM CLINICAL RESEARCH CENTERS
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202517489
Principal investigator 1 ABBVIE INC. $150.00 10/21/2025 Non-covered Recipient Entity
PARADIGM CLINICAL RESEARCH CENTERS
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202517491
Principal investigator 1 ABBVIE INC. $1,120.00 10/21/2025 Non-covered Recipient Entity
PARADIGM CLINICAL RESEARCH CENTERS
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202517507
Principal investigator 1 ABBVIE INC. $2,250.00 10/21/2025 Non-covered Recipient Entity
PARADIGM CLINICAL RESEARCH CENTERS
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202517509
Principal investigator 1 ABBVIE INC. $203.00 10/21/2025 Non-covered Recipient Entity
PARADIGM CLINICAL RESEARCH CENTERS
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202517511
Principal investigator 1 ABBVIE INC. $50.00 10/21/2025 Non-covered Recipient Entity
PARADIGM CLINICAL RESEARCH CENTERS
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202517513
Principal investigator 1 ABBVIE INC. $1,120.00 10/21/2025 Non-covered Recipient Entity
PARADIGM CLINICAL RESEARCH CENTERS
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202517515
Principal investigator 1 ABBVIE INC. $2,250.00 10/21/2025 Non-covered Recipient Entity
PARADIGM CLINICAL RESEARCH CENTERS
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202517533
Principal investigator 1 ABBVIE INC. $1,120.00 10/21/2025 Non-covered Recipient Entity
PARADIGM CLINICAL RESEARCH CENTERS
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202517535
Principal investigator 1 SANOFI PASTEUR INC. $621.18 10/15/2025 Non-covered Recipient Entity
Paradigm Clinical Research Centers, Inc
Phase III, Randomized, Single-blind, Placebo-controlled, Multi-center Study to Evaluate Non-interference of Concomitant Administration of Routine Pediatric Vaccines on the Antibody Response of an Investigational Live-attenuated Respiratory Syncytial Virus (RSV) Vaccine in Healthy Infants and Toddlers (CORAL) No dispute reported 06/30/2026 1226114350
Principal investigator 1 SANOFI PASTEUR INC. $12,600.00 10/13/2025 Non-covered Recipient Entity
Paradigm Clinical Research Centers, Inc
A Parallel Group, Phase III, Randomized, Observer Blind, Placebo Controlled, Multi Center, Multinational, Multi Arm Study to Demonstrate Non-inferiority of the Immune Response of a Low Dose Compared to the Standard Dose and to Evaluate the Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (OPAL) No dispute reported 06/30/2026 1226114342
Principal investigator 1 ABBVIE INC. $3,901.50 10/09/2025 Non-covered Recipient Entity
PARADIGM CLINICAL RESEARCH CENTERS
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202514389
Principal investigator 1 ABBVIE INC. $225.00 09/23/2025 Non-covered Recipient Entity
PARADIGM CLINICAL RESEARCH CENTERS
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202511870
Principal investigator 1 ABBVIE INC. $1,650.00 09/11/2025 Non-covered Recipient Entity
PARADIGM CLINICAL RESEARCH CENTERS
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202510634
Principal investigator 1 ABBVIE INC. $600.00 09/04/2025 Non-covered Recipient Entity
PARADIGM CLINICAL RESEARCH CENTERS
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202508812
Principal investigator 1 ABBVIE INC. $12,741.80 09/04/2025 Non-covered Recipient Entity
PARADIGM CLINICAL RESEARCH CENTERS
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202508814
Principal investigator 1 ABBVIE INC. $3,715.39 09/04/2025 Non-covered Recipient Entity
PARADIGM CLINICAL RESEARCH CENTERS
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202508816
Principal investigator 1 ABBVIE INC. $1,200.00 08/28/2025 Non-covered Recipient Entity
PARADIGM CLINICAL RESEARCH CENTERS
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202506347
Principal investigator 1 ABBVIE INC. $189.00 08/28/2025 Non-covered Recipient Entity
PARADIGM CLINICAL RESEARCH CENTERS
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202506349
Principal investigator 1 ABBVIE INC. $113.40 08/27/2025 Non-covered Recipient Entity
PARADIGM CLINICAL RESEARCH CENTERS
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202505987
Principal investigator 1 ABBVIE INC. $600.00 08/26/2025 Non-covered Recipient Entity
PARADIGM CLINICAL RESEARCH CENTERS
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202505789
Principal investigator 1 ABBVIE INC. $43.00 08/26/2025 Non-covered Recipient Entity
PARADIGM CLINICAL RESEARCH CENTERS
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202505799
Principal investigator 1 ABBVIE INC. $1,950.00 08/14/2025 Non-covered Recipient Entity
PARADIGM CLINICAL RESEARCH CENTERS
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202504693
Principal investigator 1 ABBVIE INC. $90.00 08/11/2025 Non-covered Recipient Entity
PARADIGM CLINICAL RESEARCH CENTERS
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202504185
Principal investigator 1 ABBVIE INC. $113.40 08/11/2025 Non-covered Recipient Entity
PARADIGM CLINICAL RESEARCH CENTERS
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202504187
Principal investigator 1 ABBVIE INC. $1,714.50 08/06/2025 Non-covered Recipient Entity
PARADIGM CLINICAL RESEARCH CENTERS
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202502683
Principal investigator 1 ABBVIE INC. $4,590.00 08/06/2025 Non-covered Recipient Entity
PARADIGM CLINICAL RESEARCH CENTERS
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202502815
Principal investigator 1 ABBVIE INC. $3,172.50 07/02/2025 Non-covered Recipient Entity
PARADIGM CLINICAL RESEARCH CENTERS
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202494467
Principal investigator 1 ABBVIE INC. $7,802.15 07/02/2025 Non-covered Recipient Entity
PARADIGM CLINICAL RESEARCH CENTERS
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202494475
Principal investigator 1 SANOFI PASTEUR INC. $2,345.00 06/25/2025 Non-covered Recipient Entity
Paradigm Clinical Research Centers, Inc
Phase III, Randomized, Single-blind, Placebo-controlled, Multi-center Study to Evaluate Non-interference of Concomitant Administration of Routine Pediatric Vaccines on the Antibody Response of an Investigational Live-attenuated Respiratory Syncytial Virus (RSV) Vaccine in Healthy Infants and Toddlers (CORAL) No dispute reported 06/30/2026 1226114312
Principal investigator 1 SANOFI PASTEUR INC. $737.80 06/18/2025 Non-covered Recipient Entity
Paradigm Clinical Research Centers, Inc
Phase III, Randomized, Single-blind, Placebo-controlled, Multi-center Study to Evaluate Non-interference of Concomitant Administration of Routine Pediatric Vaccines on the Antibody Response of an Investigational Live-attenuated Respiratory Syncytial Virus (RSV) Vaccine in Healthy Infants and Toddlers (CORAL) No dispute reported 06/30/2026 1226114302
Principal investigator 1 SANOFI PASTEUR INC. $210.00 06/18/2025 Non-covered Recipient Entity
Paradigm Clinical Research Centers, Inc
Phase III, Randomized, Single-blind, Placebo-controlled, Multi-center Study to Evaluate Non-interference of Concomitant Administration of Routine Pediatric Vaccines on the Antibody Response of an Investigational Live-attenuated Respiratory Syncytial Virus (RSV) Vaccine in Healthy Infants and Toddlers (CORAL) No dispute reported 06/30/2026 1226114306
Principal investigator 1 SANOFI PASTEUR INC. $128.80 06/09/2025 Non-covered Recipient Entity
Paradigm Clinical Research Centers, Inc
A Parallel Group, Phase III, Randomized, Observer Blind, Placebo Controlled, Multi Center, Multinational, Multi Arm Study to Demonstrate Non-inferiority of the Immune Response of a Low Dose Compared to the Standard Dose and to Evaluate the Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (OPAL) No dispute reported 06/30/2026 1226114288
Principal investigator 1 SANOFI PASTEUR INC. $630.00 06/09/2025 Non-covered Recipient Entity
Paradigm Clinical Research Centers, Inc
Phase III, Randomized, Single-blind, Placebo-controlled, Multi-center Study to Evaluate Non-interference of Concomitant Administration of Routine Pediatric Vaccines on the Antibody Response of an Investigational Live-attenuated Respiratory Syncytial Virus (RSV) Vaccine in Healthy Infants and Toddlers (CORAL) No dispute reported 06/30/2026 1226114296
Principal investigator 1 ABBVIE INC. $500.00 06/03/2025 Non-covered Recipient Entity
PARADIGM CLINICAL RESEARCH CENTERS
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202488867
Principal investigator 1 Masimo Corporation $2,915.00 04/03/2025 Non-covered Recipient Entity
WCG IRB, LLC
Philips FAST SpO2 Technology with Masimo sensors for SpO2 monitoring in the neonatal, infant, and pediatric populations No dispute reported 06/30/2026 1228232900
Principal investigator 1 SANOFI PASTEUR INC. $1,864.10 03/26/2025 Non-covered Recipient Entity
Paradigm Clinical Research Centers, Inc
Phase III, Randomized, Single-blind, Placebo-controlled, Multi-center Study to Evaluate Non-interference of Concomitant Administration of Routine Pediatric Vaccines on the Antibody Response of an Investigational Live-attenuated Respiratory Syncytial Virus (RSV) Vaccine in Healthy Infants and Toddlers (CORAL) No dispute reported 06/30/2026 1226114280
Principal investigator 1 ABBVIE INC. $1,791.30 03/19/2025 Non-covered Recipient Entity
PARADIGM CLINICAL RESEARCH CENTERS
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202464304
Principal investigator 1 ABBVIE INC. $1,950.00 03/19/2025 Non-covered Recipient Entity
PARADIGM CLINICAL RESEARCH CENTERS
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202464308
Principal investigator 1 SANOFI PASTEUR INC. $1,475.60 03/07/2025 Non-covered Recipient Entity
Paradigm Clinical Research Centers, Inc
Phase III, Randomized, Single-blind, Placebo-controlled, Multi-center Study to Evaluate Non-interference of Concomitant Administration of Routine Pediatric Vaccines on the Antibody Response of an Investigational Live-attenuated Respiratory Syncytial Virus (RSV) Vaccine in Healthy Infants and Toddlers (CORAL) No dispute reported 06/30/2026 1226114277
Principal investigator 1 SANOFI PASTEUR INC. $15,041.26 03/06/2025 Non-covered Recipient Entity
Paradigm Clinical Research Centers, Inc
A Parallel Group, Phase III, Randomized, Observer Blind, Placebo Controlled, Multi Center, Multinational, Multi Arm Study to Demonstrate Non-inferiority of the Immune Response of a Low Dose Compared to the Standard Dose and to Evaluate the Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (OPAL) No dispute reported 06/30/2026 1226114270
Principal investigator 1 ABBVIE INC. $1,791.30 02/26/2025 Non-covered Recipient Entity
PARADIGM CLINICAL RESEARCH CENTERS
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202453913
Principal investigator 1 SANOFI PASTEUR INC. $4,970.56 02/21/2025 Non-covered Recipient Entity
Paradigm Clinical Research Centers, Inc
Phase III, Randomized, Single-blind, Placebo-controlled, Multi-center Study to Evaluate Non-interference of Concomitant Administration of Routine Pediatric Vaccines on the Antibody Response of an Investigational Live-attenuated Respiratory Syncytial Virus (RSV) Vaccine in Healthy Infants and Toddlers (CORAL) No dispute reported 06/30/2026 1226114171
Principal investigator 1 Masimo Corporation $4,542.00 02/06/2025 Non-covered Recipient Entity
WCG IRB, LLC
Philips FAST SpO2 Technology with Masimo sensors for SpO2 monitoring in the neonatal, infant, and pediatric populations No dispute reported 06/30/2026 1228232896
Principal investigator 1 SANOFI PASTEUR INC. $899.08 02/06/2025 Non-covered Recipient Entity
Paradigm Clinical Research Centers, Inc
Phase III, Randomized, Single-blind, Placebo-controlled, Multi-center Study to Evaluate Non-interference of Concomitant Administration of Routine Pediatric Vaccines on the Antibody Response of an Investigational Live-attenuated Respiratory Syncytial Virus (RSV) Vaccine in Healthy Infants and Toddlers (CORAL) No dispute reported 06/30/2026 1226114166
Principal investigator 1 SANOFI PASTEUR INC. $2,105.60 02/05/2025 Non-covered Recipient Entity
Paradigm Clinical Research Centers, Inc
Phase III, Randomized, Single-blind, Placebo-controlled, Multi-center Study to Evaluate Non-interference of Concomitant Administration of Routine Pediatric Vaccines on the Antibody Response of an Investigational Live-attenuated Respiratory Syncytial Virus (RSV) Vaccine in Healthy Infants and Toddlers (CORAL) No dispute reported 06/30/2026 1226114160
Principal investigator 1 Amgen Inc. $56,334.96 01/30/2025 Non-covered Recipient Entity
PARADIGM CLINICAL RESEARCH CENTER INC
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Children (6 to < 12 Years) and Adolescents (12 to < 18 Years) With Episodic Migraine (OASIS PEDIATRIC [EM]) No dispute reported 06/30/2026 1246646361
Principal investigator 1 ABBVIE INC. $16,325.00 01/27/2025 Non-covered Recipient Entity
PARADIGM CLINICAL RESEARCH CENTERS
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202441266
Principal investigator 1 ABBVIE INC. $16,850.00 01/27/2025 Non-covered Recipient Entity
PARADIGM CLINICAL RESEARCH CENTERS
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202441270
Principal investigator 1 SANOFI PASTEUR INC. $3,255.70 01/22/2025 Non-covered Recipient Entity
Paradigm Clinical Research Centers, Inc
Phase III, Randomized, Single-blind, Placebo-controlled, Multi-center Study to Evaluate Non-interference of Concomitant Administration of Routine Pediatric Vaccines on the Antibody Response of an Investigational Live-attenuated Respiratory Syncytial Virus (RSV) Vaccine in Healthy Infants and Toddlers (CORAL) No dispute reported 06/30/2026 1226114177
Principal investigator 1 SANOFI PASTEUR INC. $4,362.92 01/03/2025 Non-covered Recipient Entity
Paradigm Clinical Research Centers, Inc
Phase III, Randomized, Single-blind, Placebo-controlled, Multi-center Study to Evaluate Non-interference of Concomitant Administration of Routine Pediatric Vaccines on the Antibody Response of an Investigational Live-attenuated Respiratory Syncytial Virus (RSV) Vaccine in Healthy Infants and Toddlers (CORAL) No dispute reported 06/30/2026 1226114154